Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Stomach Neoplasms 40Carcinoma, Non-Small-Cell Lung 35Lung Neoplasms 13Neoplasms 12Adenocarcinoma 11Neoplasm Metastasis 10Colorectal Neoplasms 9Esophageal Neoplasms 7Carcinoma, Hepatocellular 7Colonic Neoplasms 5Carcinoma, Renal Cell 5Breast Neoplasms 5Adenocarcinoma Of Esophagus 5Urinary Bladder Neoplasms 3Urethral Neoplasms 3Rectal Neoplasms 3Melanoma 3Liver Neoplasms 3Carcinoma, Transitional Cell 3Biliary Tract Neoplasms 3Ureteral Neoplasms 2Thymoma 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Sarcoma 2Recurrence 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Non-small Cell Lung Cancer Metastatic 2Metastatic Gastric Adenocarcinoma 2

Interventions

pembrolizumab 3Ramucirumab 2Nivolumab 2etirinotecan pegol 1cemiplimab 1Ribavirin 1Paclitaxel 1Injections 1Fluorouracil 1Docetaxel 1Decitabine 1Cisplatin 1Carboplatin 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Malignant Solid Tumor × Ramucirumab × Clear all
NCT01515306 2022-03-08

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

Eli Lilly and Company

Phase 2 Completed
48 enrolled 17 charts
Other solid neoplasm

Malignant Solid Tumor

NCT01567163 2014-10-16

A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors

Eli Lilly and Company

Phase 2 Completed
22 enrolled 15 charts
Other solid neoplasm

Malignant Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡